Skip to main content
SpringerLink
Log in

Management of Endometrial Cancer Precursors in Obese Women

  • Chapter
  • First Online:
Focus on Gynecologic Malignancies

Part of the book series: Energy Balance and Cancer ((EBAC,volume 13))

  • 560 Accesses

Abstract

Endometrial cancer can generally be divided into two clinical subtypes, designated as type I and type II disease, each with different risk factors, histology, genetics, treatment and prognosis. Type I endometrial cancer, or low grade endometrioid adenocarcinoma, accounts for 80–90% of new cases of endometrial cancer. Endometrioid endometrial cancer is strongly associated with unopposed estrogen exposure (such as hormone replacement therapy) and obesity. Type II endometrial cancers, including clear cell carcinoma and uterine papillary serous carcinoma, are relatively rare. While the etiology of these rare tumors is not well understood, type II endometrial cancers are not associated with obesity. As such, this chapter will focus on low grade endometrioid (type I) endometrial cancer and its precursor lesions. Due to the close connection between obesity and endometrioid endometrial cancer, obese women are at increased risk for precancerous lesions and low grade endometrial cancers, and consideration is warranted for management of these conditions in the obese population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, et al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol. 2013;209(6):579 e1–5.

    Article  Google Scholar 

  2. Sivridis E, Giatromanolaki A. The pathogenesis of endometrial carcinomas at menopause: facts and figures. J Clin Pathol. 2011;64(7):553–60.

    Article  PubMed  Google Scholar 

  3. Charalampakis V, Tahrani AA, Helmy A, Gupta JK, Singhal R. Polycystic ovary syndrome and endometrial hyperplasia: an overview of the role of bariatric surgery in female fertility. Eur J Obstet Gynecol Reprod Biol. 2016;207:220–6.

    Google Scholar 

  4. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011;204(4):355 e1–7.

    Article  CAS  Google Scholar 

  5. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomark Prev. 2007;16(2):276–80.

    Article  Google Scholar 

  6. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125(3):751–7.

    Article  CAS  PubMed  Google Scholar 

  7. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205(6):518–25.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Parkash V, Fadare O, Tornos C, WG MC, Committee Opinion No. 631. Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2015;126(4):897.

    Article  PubMed  Google Scholar 

  9. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56(2):403–12.

    Article  CAS  PubMed  Google Scholar 

  10. Huang M, Djordjevic B, Yates MS, Urbauer D, Sun C, Burzawa J, et al. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013;119(16):3027–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009;200(6):678 e1–6.

    Article  Google Scholar 

  12. Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012;19(5):562–71.

    Article  PubMed  Google Scholar 

  13. Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol. 2008;168(6):563–70. discussion 71–6

    Article  PubMed  PubMed Central  Google Scholar 

  14. Argenta PA, Kassing M, Truskinovsky AM, Svendsen CA. Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study. BJOG. 2013;120(7):795–800.

    Article  CAS  PubMed  Google Scholar 

  15. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Levitt J, et al. Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol. 2014;124(2 Pt 1):300–6.

    Article  PubMed  Google Scholar 

  16. Soliman PT, Bassett RL Jr, Wilson EB, Boyd-Rogers S, Schmeler KM, Milam MR, et al. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol. 2008;112(4):835–42.

    Article  PubMed  Google Scholar 

  17. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):804–11.

    Article  PubMed  Google Scholar 

  18. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812–9.

    Article  PubMed  Google Scholar 

  19. Matsuo K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, Machida H, Moeini A, et al. Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol. 2015;139(2):261–7.

    Article  PubMed  Google Scholar 

  20. Practice Bulletin No. 149. Endometrial cancer. Obstet Gynecol. 2015;125(4):1006–26.

    Article  Google Scholar 

  21. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88–105.

    Article  PubMed  Google Scholar 

  22. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14–22.

    Article  PubMed  PubMed Central  Google Scholar 

  23. American College of O, Gynecologists. ACOG committee opinion no. 557. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891–6.

    Article  CAS  Google Scholar 

  24. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46.

    Article  PubMed  Google Scholar 

  25. Ben-Baruch G, Seidman DS, Schiff E, Moran O, Menczer J. Outpatient endometrial sampling with the Pipelle curette. Gynecol Obstet Investig. 1994;37(4):260–2.

    Article  CAS  Google Scholar 

  26. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Rabbitt C, Chi DS, et al. Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. Am J Obstet Gynecol. 2010;202(3):278 e1–6.

    Article  Google Scholar 

  27. Costales AB, Schmeler KM, Broaddus R, Soliman PT, Westin SN, Ramirez PT, et al. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014;135(3):451–4.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Suh-Burgmann E, Hung YY, Armstrong MA. Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol. 2009;114(3):523–9.

    Article  PubMed  Google Scholar 

  29. Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280(17):1510–7.

    Article  CAS  PubMed  Google Scholar 

  30. American College of O, Gynecologists. ACOG Committee Opinion No. 440. The role of Transvaginal ultrasonography in the evaluation of postmenopausal bleeding. Obstet Gynecol. 2009;114(2 Pt 1):409–11.

    Google Scholar 

  31. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol. 2012;120(5):1160–75.

    PubMed  PubMed Central  Google Scholar 

  32. Kim MJ, Kim JJ, Kim SM. Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women. Obstet Gynecol Sci. 2016;59(3):192–200.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014;133(2):283–6.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Stephan JM, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, et al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol. 2014;133(3):499–505.

    Article  PubMed  Google Scholar 

  35. Morotti M, Menada MV, Moioli M, Sala P, Maffeo I, Abete L, et al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecol Oncol. 2012;125(3):536–40.

    Article  PubMed  Google Scholar 

  36. Hareyama H, Hada K, Goto K, Watanabe S, Hakoyama M, Oku K, et al. Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study. Int J Gynecol Cancer. 2015;25(4):751–7.

    Article  PubMed  Google Scholar 

  37. Orekoya O, Samson ME, Trivedi T, Vyas S, Steck SE. The impact of obesity on surgical outcome in endometrial cancer patients: a systematic review. J Gynecol Surg. 2016;32(3):149–57.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Parkin L, Sweetland S, Balkwill A, Green J, Reeves G, Beral V, et al. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation. 2012;125(15):1897–904.

    Article  PubMed  Google Scholar 

  39. Bouwman F, Smits A, Lopes A, Das N, Pollard A, Massuger L, et al. The impact of BMI on surgical complications and outcomes in endometrial cancer surgery–an institutional study and systematic review of the literature. Gynecol Oncol. 2015;139(2):369–76.

    Article  PubMed  Google Scholar 

  40. Kondalsamy-Chennakesavan S, Janda M, Gebski V, Baker J, Brand A, Hogg R, et al. Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012;48(14):2155–62.

    Article  PubMed  Google Scholar 

  41. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331–6.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Olsen MA, Higham-Kessler J, Yokoe DS, Butler AM, Vostok J, Stevenson KB, et al. Developing a risk stratification model for surgical site infection after abdominal hysterectomy. Infect Control Hosp Epidemiol. 2009;30(11):1077–83.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Nugent EK, Hoff JT, Gao F, Massad LS, Case A, Zighelboim I, et al. Wound complications after gynecologic cancer surgery. Gynecol Oncol. 2011;121(2):347–52.

    Article  PubMed  Google Scholar 

  44. Obermair A, Brennan DJ, Baxter E, Armes JE, Gebski V, Janda M. Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. Gynecol Oncol Res Pract. 2016;3:1.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE Jr. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117(4):877–82.

    Article  PubMed  Google Scholar 

  46. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect. 2013;14(1):73–156.

    Article  Google Scholar 

  47. Chan JK, Gardner AB, Taylor K, Thompson CA, Blansit K, Yu X, et al. Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates. Gynecol Oncol. 2015;139(2):300–5.

    Article  PubMed  Google Scholar 

  48. Cosin JA, Brett Sutherland MA, Westgate CT, Fang H. Complications of robotic gynecologic surgery in the severely morbidly obese. Ann Surg Oncol. 2016;23(12):4035–41.

    Article  PubMed  Google Scholar 

  49. Committee on Gynecologic P. Committee opinion no. 619. Gynecologic surgery in the obese woman. Obstet Gynecol. 2015;125(1):274–8.

    Article  Google Scholar 

  50. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575–80.

    Article  PubMed  Google Scholar 

  51. Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1–8.

    Google Scholar 

  52. Wise MR, Jordan V, Lagas A, Showell M, Wong N, Lensen S, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol. 2016;214(6):689 e1–e17.

    Article  Google Scholar 

  53. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev. 2002;11(12):1531–43.

    CAS  Google Scholar 

  54. Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia–precursor of endometrial cancer. Gynecol Oncol. 2003;88(2):108–17.

    Article  CAS  PubMed  Google Scholar 

  55. Salman MC, Usubutun A, Boynukalin K, Yuce K. Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. J Gynecol Oncol. 2010;21(2):97–101.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Yu M, Yang JX, Wu M, Lang JH, Huo Z, Shen K. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril. 2009;92:2122–4.

    Article  PubMed  Google Scholar 

  57. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798–803.

    Article  CAS  PubMed  Google Scholar 

  58. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31:988–98.

    Article  PubMed  Google Scholar 

  59. Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett. 2007;248:112–22.

    Article  CAS  PubMed  Google Scholar 

  60. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014;121(4):477–86.

    Article  CAS  PubMed  Google Scholar 

  61. Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016;132:34–8.

    Article  PubMed  Google Scholar 

  62. Kudesia R, Singer T, Caputo TA, Holcomb KM, Kligman I, Rosenwaks Z, Gupta D. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. Am J Obstet Gynecol. 2014;210:1–4.

    Article  CAS  Google Scholar 

  63. Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015;291:151–7.

    Article  CAS  PubMed  Google Scholar 

  64. Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27(2):262–6.

    Article  CAS  PubMed  Google Scholar 

  65. Wildemeersch D, Janssens D, Vrijens M, Weyers S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception. 2005;71(6):465–9.

    Article  CAS  PubMed  Google Scholar 

  66. Tjalma WAA, Janssens D, Wildemeersch D, Colpaert C, Watty K. Conservative management of atypical endometrial hyperplasia and early invasive carcinoma with intrauterine levonorgestrel: a progesterone receptor study. EJC Suppl. 2004;2:93–4.

    Google Scholar 

  67. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82.

    Article  CAS  PubMed  Google Scholar 

  68. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1):e8.

    Article  PubMed  Google Scholar 

  69. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Clinical performance of a new levonorgestrel-releasing intrauterine device. A randomized comparison with a nova-T-copper device. Contraception. 1982;25(4):345–56.

    Article  CAS  PubMed  Google Scholar 

  70. Lahteenmaki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids. 2000;65(10-11):693–7.

    Article  CAS  PubMed  Google Scholar 

  71. Bafaloukos D, Aravantinos G, Samonis G, Katsifis G, Bakoyiannis C, Skarlos D, et al. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study. Oncology. 1999;56(3):198–201.

    Article  CAS  PubMed  Google Scholar 

  72. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001;167(1):39–48.

    Article  CAS  PubMed  Google Scholar 

  73. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736–44.

    Article  CAS  PubMed  Google Scholar 

  74. Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ 3rd. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. Gynecol Oncol. 2016;140(2):234–8.

    Article  CAS  PubMed  Google Scholar 

  75. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700.

    Article  CAS  PubMed  Google Scholar 

  76. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547 e1–10.

    Article  CAS  Google Scholar 

  77. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121(6):1165–71.

    Article  CAS  PubMed  Google Scholar 

  78. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia–a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):169–75.

    Article  CAS  PubMed  Google Scholar 

  79. Orbo A, Arnes M, Vereide AB, Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2016;123(9):1512–9.

    Article  CAS  PubMed  Google Scholar 

  80. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266 e1–12.

    Article  Google Scholar 

  81. Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121(1):136–42.

    Article  PubMed  Google Scholar 

  82. Kalogera E, Dowdy SC, Bakkum-Gamez JN. Preserving fertility in young patients with endometrial cancer: current perspectives. Int J Womens Health. 2014;6:691–701.

    PubMed  PubMed Central  Google Scholar 

  83. Koskas M, Uzan J, Luton D, Rouzier R, Darai E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101(3):785–94.

    Article  PubMed  Google Scholar 

  84. Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol. 1997;65(1):102–14.

    Article  CAS  PubMed  Google Scholar 

  85. Perez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol. 1999;73(2):299–304.

    Article  CAS  PubMed  Google Scholar 

  86. Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V, Saravelos H, et al. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas. 2004;48(2):125–32.

    Article  CAS  PubMed  Google Scholar 

  87. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3(11):1451–61.

    Article  CAS  Google Scholar 

  88. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767–80.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Shan W, Wang C, Zhang Z, Gu C, Ning C, Luo X, et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. J Gynecol Oncol. 2014;25(3):214–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Hawkes AL, Quinn M, Gebski V, Armes J, Brennan D, Janda M, et al. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device +/− metformin +/− weight loss in endometrial cancer (feMME) trial. Contemp Clin Trials. 2014;39(1):14–21.

    Article  CAS  PubMed  Google Scholar 

  92. Milam MR, Celestino J, Wu W, Broaddus RR, Schmeler KM, Slomovitz BM, et al. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol. 2007;196(3):247 e1–5.

    Article  CAS  Google Scholar 

  93. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Smits A, Lopes A, Das N, Bekkers R, Massuger L, Galaal K. The effect of lifestyle interventions on the quality of life of gynaecological cancer survivors: A systematic review and meta-analysis. Gynecol Oncol. 2015;139(3):546–52.

    Article  PubMed  Google Scholar 

  95. Hall C, Stone RL, Gehlot A, Zorn KK, Burnett AF. Use of metformin in obese women with type I endometrial cancer is associated with a reduced incidence of cancer recurrence. Int J Gynecol Cancer. 2016;26(2):313–7.

    Article  PubMed  Google Scholar 

  96. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720–32.

    Article  CAS  PubMed  Google Scholar 

  97. Modesitt SC, Hallowell PT, Slack-Davis JK, Michalek RD, Atkins KA, Kelley SL, et al. Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Gynecol Oncol. 2015;138(2):238–45.

    Article  PubMed  Google Scholar 

  98. Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol. 2011;120(1):43–6.

    Article  PubMed  Google Scholar 

  99. Mazzon I, Corrado G, Morricone D, Scambia G. Reproductive preservation for treatment of stage IA endometrial cancer in a young woman: hysteroscopic resection. Int J Gynecol Cancer. 2005;15(5):974–8.

    Article  CAS  PubMed  Google Scholar 

  100. De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, et al. Hysteroscopic resection in fertility-sparing surgery for atypical hyperplasia and endometrial cancer: safety and efficacy. J Minim Invasive Gynecol. 2015;22(7):1178–82.

    Article  PubMed  Google Scholar 

  101. Mayor PC, Lele S. Photodynamic therapy in gynecologic malignancies: a review of the Roswell Park Cancer Institute experience. Cancers (Basel). 2016;8(10):E88.

    Article  Google Scholar 

  102. Choi MC, Jung SG, Park H, Cho YH, Lee C, Kim SJ. Fertility preservation via photodynamic therapy in young patients with early-stage uterine endometrial cancer: a long-term follow-up study. Int J Gynecol Cancer. 2013;23(4):698–704.

    Article  PubMed  Google Scholar 

  103. Gezginc ST, Celik C, Dogan NU, Toy H, Tazegul A, Colakoglu MC. Expression of cyclin A, cyclin E and p27 in normal, hyperplastic and frankly malignant endometrial samples. J Obstet Gynaecol. 2013;33(5):508–11.

    Article  CAS  PubMed  Google Scholar 

  104. McCampbell AS, Mittelstadt ML, Dere R, Kim S, Zhou L, Djordjevic B, et al. Loss of p27 associated with risk for endometrial carcinoma arising in the setting of obesity. Curr Mol Med. 2016;16(3):252–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, et al. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015;9(8):1694–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Gallos ID, Devey J, Ganesan R, Gupta JK. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study. Gynecol Oncol. 2013;130(1):58–63.

    Article  CAS  PubMed  Google Scholar 

  107. Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014;50(17):3003–10.

    Article  CAS  PubMed  Google Scholar 

  108. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Jusko WJ. Clarification of contraceptive drug pharmacokinetics in obesity. Contraception. 2016;95(1):10–6.

    Article  PubMed  CAS  Google Scholar 

  110. Simmons KB, Edelman AB. Hormonal contraception and obesity. Fertil Steril. 2016;106(6):1282–8.

    Google Scholar 

  111. Azran C, Wolk O, Zur M, Fine-Shamir N, Shaked G, Czeiger D, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev. 2016;17(11):1050–66.

    Article  PubMed  Google Scholar 

  112. Nelson A, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1205–13.

    Article  CAS  PubMed  Google Scholar 

  113. Panoulas VF, Mastoris I, Konstantinou K, Tespili M, Ielasi A. Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. Med Devices (Auckl). 2015;8:317–29.

    Google Scholar 

  114. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12(5):1073–9.

    Article  CAS  PubMed  Google Scholar 

  115. Ficicioglu C, Gurbuz B, Tasdemir S, Yalti S, Canova H. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol. 2004;18(5):240–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Unit 1362, Houston, TX, 77030, USA

    Joseph A. Dottino & Melinda S. Yates

  2. Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX, USA

    Karen H. Lu

Authors
  1. Joseph A. Dottino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen H. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melinda S. Yates
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melinda S. Yates .

Editor information

Editors and Affiliations

  1. Center for Science, Health and Society, Case Western Reserve University, Cleveland, Ohio, USA

    Nathan A. Berger

  2. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA

    Ann H. Klopp

  3. Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, Texas, USA

    Karen H. Lu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Dottino, J.A., Lu, K.H., Yates, M.S. (2018). Management of Endometrial Cancer Precursors in Obese Women. In: Berger, N., Klopp, A., Lu, K. (eds) Focus on Gynecologic Malignancies. Energy Balance and Cancer, vol 13. Springer, Cham. https://doi.org/10.1007/978-3-319-63483-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63483-8_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63482-1

  • Online ISBN: 978-3-319-63483-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation